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Abstract
Background: Standard prehospital management for Acute respiratory failure (ARF) involves controlled oxygen
therapy. Continuous positive airway pressure (CPAP) is a potentially beneficial alternative treatment, however, it is
uncertain whether this could improve outcomes and provide value for money. This study aimed to evaluate the
cost-effectiveness of prehospital CPAP in ARF.
Methods: A cost-utility economic evaluation was performed using a probabilistic decision tree model synthesising
available evidence. The model consisted of a hypothetical cohort of patients in a representative ambulance service
with undifferentiated ARF, receiving standard oxygen therapy or prehospital CPAP. Costs and quality adjusted life
years (QALYs) were estimated using methods recommended by NICE.
Results: In the base case analysis, using CPAP effectiveness estimates form the ACUTE trial, the mean expected costs of
standard care and prehospital CPAP were £15,201 and £14,850 respectively and the corresponding mean expected QALYs
were 1.190 and 1.128, respectively. The mean ICER estimated as standard oxygen therapy compared to prehospital CPAP
was £5685 per QALY which indicated that standard oxygen therapy strategy was likely to be cost-effective at a threshold of
£20,000 per QALY (67% probability). The scenario analysis, using effectiveness estimates from an updated meta-analysis,
suggested that prehospital CPAP was more effective (mean incremental QALYs of 0.157), but also more expensive (mean
incremental costs of £1522), than standard care. The mean ICER, estimated as prehospital CPAP compared to standard care,
was £9712 per QALY. At the £20,000 per QALY prehospital CPAP was highly likely to be the most cost-effective strategy
(94%).
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Conclusions: Cost-effectiveness of prehospital CPAP depends upon the estimate of effectiveness. When based on a small
pragmatic feasibility trial, standard oxygen therapy is cost-effective. When based on meta-analysis of heterogeneous trials,
CPAP is cost-effective. Value of information analyses support commissioning of a large pragmatic effectiveness trial, providing
feasibility and plausibility conditions are met.
Keywords: Cost-effectiveness, Continuous positive airway pressure, Acute respiratory failure
What is already known on this subject
 A recent meta-analysis suggested that prehospital
continuous positive airway pressure (CPAP) deliv-
ered by emergency medical services is a potentially
beneficial alternative to standard oxygen treatment
for acute respiratory failure (ARF).
 Previous cost-effectiveness analysis suggest that pre-
hospital CPAP could provide value for money. How-
ever, they were performed using ARF incidence
estimates and clinical outcomes from the meta-
analysis which may not be generalizable to the UK
setting.
What this study adds
 This study estimates the cost-effectiveness of pre-
hospital CPAP in patients with ARF using data spe-
cific to the UK setting based on the findings of the
ACUTE feasibility trial. Value of information ana-
lyses support commissioning of a large pragmatic ef-
fectiveness trial, providing feasibility and plausibility
conditions are met.
Background
Acute respiratory failure (ARF) is a common and life-
threatening medical emergency [1]. ARF has substantial
health services costs, with patients often requiring pro-
longed hospital stays, ventilatory support and critical
care admissions. Incidence of ARF has been estimated at
80 cases per 100,000 per year; and ARF has substantial
health services costs (estimated at £9.6 million per year
in England [2]), with patients often requiring prolonged
hospital stays [3], ventilatory support and critical care
admissions [4, 5].
Prehospital continuous positive airway pressure (CPAP)
is a potentially beneficial alternative to standard oxygen
treatment for ARF that could be delivered by emergency
medical services [6]. A recent meta-analysis suggested that
out-of-hospital CPAP could decrease mortality in ARF [2].
An economic evaluation using the estimates from the
same meta-analysis suggested that while prehospital CPAP
was more effective than standard care it was also more ex-
pensive [6]. Cost-effectiveness was consequently uncer-
tain, with an incremental cost-effectiveness ratio of £20,
514/quality adjusted life year (QALY) and a 49.5% prob-
ability of being cost-effective at the £20,000/QALY thresh-
old. These estimates were predicated on the incidence of
ARF and the accuracy of effectiveness data captured from
the meta-analysis. However, included studies were at risk
of bias and the methods used to deliver prehospital CPAP
(physician or paramedics with online physician support)
do not reflect systems that primarily use unsupported
paramedics to deliver care, such as the UK National
Health Service (NHS).
The Ambulance CPAP: Use, Treatment effect and eco-
nomics (ACUTE) randomised controlled pilot trial [7, 8]
was conducted to understand whether CPAP could be
delivered effectively by unsupported paramedics and if it
represents value for money. This study investigated the
cost-effectiveness of prehospital CPAP compared with
standard care for patients with ARF, using ARF inci-
dence estimates and clinical outcomes from the ACUTE
trial. Specific objectives were a) to estimate the cost-
effectiveness of pre-hospital CPAP compared with stand-
ard care for patients with ARF, in terms of the costs and
quality adjusted life years (QALYs) gained; b) Identify
whether prehospital CPAP is likely to be cost-effective
for patients with ARF at conventional willingness to pay
thresholds; and c) evaluate the cost and value of under-




The decision problem was ‘which is the most cost-
effective treatment strategy for patients presenting to
UK ambulance services with ARF?’ A cost-utility eco-
nomic evaluation was performed using a probabilistic
decision analytic model to synthesise available evidence
and compare alternative management strategies [9, 10].
Data from ACUTE trial is used in the base case – the ra-
tionale is that it is most relevant data for paramedic led
services such as the NHS even though it is an imprecise
effect estimate; and the aim of the model is to evaluate
existing uncertainty around the decision problem rele-
vant to this setting. Principles for economic evaluations
outlined in the National Institute for Health and Care
Excellence (NICE) Guide to the Methods of Technology
Appraisal were followed [11]. The economic perspective
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was the UK health service in England and Wales with
only direct treatment costs included. The model used
3.5% discount rate for costs and QALYs, and employed
a lifetime horizon.
Interventions
Any potentially relevant prehospital treatments that
could feasibly be implemented in the UK health service
for ARF were considered. However, due to the complex-
ity of alternative forms of Non-Invasive Ventilation, only
CPAP was judged as being a practicable alternative to
standard oxygen practice. Interventions therefore com-
prised: pre-hospital CPAP provided by ambulance ser-
vice clinicians and standard oxygen therapy i.e. without
pre-hospital CPAP. Hospital management was assumed
identical for both comparators.
Model population and setting
The population consisted of a hypothetical cohort of pa-
tients with acute respiratory failure from any cause and
potentially suitable for CPAP treatment and the setting
was a representative ambulance service, such as West
Midland Ambulance Service (WMAS) – setting for the
ACUTE feasibility trial. Although this cohort could in-
clude patients with heterogeneous aetiology for ARF, in-
cluding acute cardiogenic pulmonary oedema/heart
failure, chronic obstructive pulmonary disease and pneu-
monia, for the purposes of modelling they were treated
as a single group.
Model structure
The model structure was based on a previously pub-
lished economic model, as presented in Fig. 1. Patients
received prehospital CPAP in the intervention group
and standard care in the comparator group, and the
treatment choice affected the probability of death and
probability of intubation. The model assigned a baseline
probability of intubation or death within 30 days for the
standard care arm; and the intervention arm probabil-
ities were estimated by applying log odds ratios (ORs) to
the baseline risks. Patients who survived accrued lifetime
QALYs and health care costs according to their life ex-
pectancy. Costs were also accrued through costs of inter-
vention (i.e., out-of-hospital CPAP) and hospital
treatment costs, which depended on whether the patient
needed intubation. A summary of the parameters used
in the model are reported in Table 1.
Analyses were performed using different effectiveness
parameters. In the base case, effectiveness data from the
ACUTE pilot trial were used as it is the most representa-
tive data for paramedic led services such as the NHS, even
though it is an imprecise estimate. As a pragmatic trial,
ACUTE used minimal exclusion criteria to select patients
and CPAP was delivered using a simple disposable unit
(O-Two [13]) by ambulance clinicians without extended
or specialist training. A scenario analysis was undertaken
using effectiveness parameters a recent network meta-
analysis synthesising previously published experimental
data, updated with results from the ACUTE study, using
identical methods to those previously reported. The other
studies included in the meta-analysis used less pragmatic
inclusion criteria, more complex CPAP delivery systems
and involved physicians or paramedics with online phys-
ician support to deliver the interventions. From the per-
spective of an ambulance service based on unsupported
ambulance clinicians, the ACUTE data provide a relatively
imprecise estimate of effectiveness (i.e. how the interven-
tion works in usual practice), while the meta-analysis pro-
vides a more precise estimate of efficacy (i.e. how the
intervention could work in certain circumstances).
Fig. 1 Structure of the decision analytic model
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Data
Parameter estimates, distributional forms and data
sources are summarized in Table 1. The baseline risk of
mortality was modelled using the 30-day mortality data
from control arm of the ACUTE pilot trial which re-
ported 9 deaths (25.7%, n = 35, complete case, modified
intention to treat analysis set). The intubation risk,
which determines whether critical care admission is re-
quired, was also modelled using the data from control
arm of the ACUTE trial, which reported one intubation
(3.4%, n = 29, complete case, modified intention to treat
analysis set).
The base case analysis used relative effectiveness re-
sults from the ACUTE pilot trial for mortality and in-
tubation. The odds ratios (OR) for effectiveness of
CPAP for reducing mortality and intubation were 1.2
(95% CI 0.4 to 3.2) and 1.8 (95% CI 0.2 to 40.1) re-
spectively. A scenario analysis was also performed
using network meta-analysis [2] revised with results
from the ACUTE study, using identical methods to
those previously reported. The odds ratios (OR) with
95% credible intervals for reducing mortality and in-
tubation were 0.5 (95%CI 0.2 to 1.4) and 0.4 (0.1 to
0.9) respectively [8].
Lifetime QALYs for surviving patients were estimated
by multiplying the life years with representative quality
of life using same estimates as in the previous economic
model [2]; both derived from the 3CPO trial [12].
Discounted life expectancy was estimated at 2.67 years
and the mean utility value was 0.6.
The costs included in the model are for prehospital
CPAP, intubation, hospitalization, and lifetime care for
patients. We estimated the costs of prehospital CPAP at
an ambulance service level and converted these into a
cost per patient according to a 5-year depreciation
period. These costs included those for initial equipment,
implementation, and ongoing maintenance. This re-
sulted in a final CPAP cost per patient ranging from
£26.53 to £39.57, which was assumed to be normally dis-
tributed around the mean of £33.00 with a standard de-
viation of £3.30. More details about the prehospital
CPAP costing is provided in Additional file 1.
The cost of intubation was estimated in the previous
HTA economic model by multiplying intensive care unit
costs by the average length of stay for intubation as-
sumed to be 5 days. These costs were inflated and this
resulted in a mean annual cost of £3600 which was para-
meterised as a gamma distribution with an alpha of 90
and a beta of 40, after consultation with ACUTE study
clinical experts.
The hospitalisation costs were estimated as weighted
average costs of non-intubated patients in the ACUTE
trial that received NIV in hospital (approximately 42.5%
between both arms) and that did not, which corre-
sponded to patients with NHS Reference Cost codes
DZ27S (respiratory Failure without Interventions, with
Table 1 Summary of model parameters
Parameter Mean Distribution or 95% CI Source
Baseline risks
Risk of mortality 0.257 Beta (9,26) ACUTE
Risk of intubation 0.034 Beta (1,28) ACUTE
OR for prehospital CPAP
Base case scenario (effectiveness parameters from ACUTE)
Log (Mortality OR) 0.145 Normal (0.145, 0.521) ACUTE
Log (Intubation OR) 0.591 Normal (0.591, 1.403) ACUTE
Scenario using effectiveness parameters from NMA
Log (Mortality OR) −0.916 Samples ACUTE, HTA meta-analysis [2]
Log (Intubation OR) −1.050 Samples ACUTE, HTA meta-analysis [2]
Life expectancy of patients
Lifetime years 2.67 years Normal (2.67, 0.16) 3CPO trial [12], Clinical opinion
Health related quality of life
Utility 0.6 Beta (640,425) 3CPO trial [12], Clinical opinion
Costs (in £)
Prehospital CPAP £33 Normal (£33, £3.3) O-Two/SP [13], WMAS, Expert opinion
Hospitalisation £3200 Gamma (80,40) NHS Reference Costs [14]
Intubation £3600 Gamma (90, 40) HCHS index [15], Clinical opinion
Annual costs £6000 Gamma (60, 100) 3CPO trial [12], HCHS index [15], Clinical opinion
HCHS Hospital and Community Health Services, WMAS West Midland Ambulance Service.
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CC Score 11+) and patients with code DZ27P (respira-
tory Failure with Single Intervention, with CC Score 11+
), respectively based on expert clinical input. Thus, the
mean inpatient admission cost for hospitalisations was
calculated as weighted average of the costs of patients
with DZ27S and DZ27P, from the NHS Reference Costs
for 2016–17 [14], resulting in a mean cost of £3200 and
represented as gamma distribution with an alpha of 80
and a beta of 40.
Lifetime costs of survivors were estimated using the
annual costs and the discounted life expectancy of pa-
tients captured from the 3CPO trial [12], which were in-
flated resulting in a mean annual cost of £6000. In the
model, this annual cost was parameterised as a gamma
distribution with an alpha of 60 and a beta of 100, after
discussions with ACUTE clinical experts. It was assumed
that the lifetime costs were the same for all survivors, ir-
respective of whether they were in the standard care or
prehospital CPAP arm.
Cost-effectiveness analysis
The cost-effectiveness was estimated using both the
incremental cost effectiveness ratios (ICER) and the
net monetary benefit (NMB) approaches. The ICER is
calculated as the mean incremental cost divided by
the mean incremental benefits, computed by compar-
ing to the next most effective alternative. The willing-
ness to pay threshold (λ) is the amount of money
that the decision-maker is willing to pay to gain an
additional QALY [16]. The usual threshold for
decision-making in the UK is based on information
from NICE, and considered to be £20,000 per QALY
as detailed in NICE HTA guidelines. This effectively
means that NICE will recommend an intervention for
funding if it can deliver health gain at a cost no
greater than £20,000 per QALY compared to the next
most effective alternative. The NMB framework trans-
forms cost-effectiveness results to a linear scale; it is
defined as the QALYs multiplied by a value for the
QALYs (e.g. £20,000) minus the costs of obtaining
them: NMB = (QALYs × λ) – cost. The strategy with
the highest expected incremental net monetary benefit
is the most cost-effective [9, 17].
Probabilistic sensitivity analysis
In order to account for the uncertainty in model inputs
a probabilistic sensitivity analysis (PSA) was conducted
using Monte Carlo simulation [9, 17, 18] Multiple model
runs were performed, each with a random draw from
every parameter’s probabilistic distribution, thus evaluat-
ing the full range of cost-effectiveness results possible
given the uncertainty on model inputs [9, 17, 18]. Mean
ICERs calculated from the average expected costs and
effects over all model runs, were computed and
compared with cost-effectiveness thresholds to inform
adoption decisions. The incremental costs and of each
model run were depicted graphically on a cost-
effectiveness plane. A cost-effectiveness acceptability
curve (CEAC), plotting a relevant range of λ values
against the probability that each intervention was the
most cost-effective, was also graphed to summarise the
uncertainty of PSA results [19].
Value of information analysis
The population expected value of perfect information
(EVPI) places an upper limit on what healthcare system
should be willing to pay for additional evidence to re-
move decision uncertainty i.e. EVPI informs the future
total value of addition research relating to a specific de-
cision problem [9, 12]. The population expected value of
partial perfect information (EVPPI) is the value in im-
proving the precision of estimates of parameters, or
groups of parameters.
Individual level expected value of information metrics
were initially calculated for both the base case and up-
dated meta-analysis scenario analysis. EVPI for individ-
ual patients was directly calculated directly from the
model PSA output using standard formulas [9] and indi-
vidual EVPPI values were estimated by using 2 level
Monte Carlo simulation techniques [20]. Assumptions
on ARF incidence (11,000 patients per year in England
and Wales) and health technology lifespan (5 years) were
used to compute population level results.
Results
Base case cost-effectiveness results: effectiveness
estimates from ACUTE pilot trial
The base case analysis indicated that the prehospital
CPAP strategy was cheaper and less effective than stand-
ard care. The ICER was therefore interpreted as the in-
cremental costs and QALYs of standard care compared
to CPAP (because the ICER is calculated by comparing
to the next most effective alternative).
The mean expected costs of standard care and prehos-
pital CPAP were £15,201 and £14,850 respectively. The
corresponding mean expected QALYs were 1.190 and
1.128. The mean ICER, estimated as standard care com-
pared to CPAP, was £5685 per QALY. Given the typical
NICE threshold of £20,000 per QALY, the base case ana-
lysis indicates that standard care is cost-effective because
it gains QALYs with an acceptable ICER compared to
CPAP. Table 2 summarises mean expected costs and
QALYS, ICERs and NMB for the base case analysis.
Scatterplots of the incremental expected costs and
QALYs from the PSA are shown in Fig. 2, which sug-
gests a large degree of uncertainty, reflected in the dis-
persal of PSA simulations, falling in both the North East
and South West quadrants of the cost-effectiveness
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plane. The base case cost-effectiveness acceptability
curve (CEAC) is shown in Fig. 3. At thresholds less than
£5000 per QALY, prehospital CPAP was the most cost-
effective strategy in the majority of model runs, however,
at thresholds beyond £5000 per QALY, standard care
has more probability of being cost-effective and at the
£20,000 per QALY threshold, standard care was most
likely to be cost-effective (67%).
Scenario analyses results: effectiveness estimates from
Updated network meta-analysis.
A scenario analysis indicated that the prehospital
CPAP strategy was more expensive and more effective
than standard care. The ICER was therefore interpreted
as the incremental costs and QALYs of prehospital
CPAP compared to standard care (because the ICER is
calculated by comparing to the next most effective
alternative).
The mean expected costs of standard oxygen ther-
apy and prehospital CPAP were £15,201 and £16,722
respectively. The corresponding mean expected
QALYs were 1.19 and 1.35. The mean ICER, esti-
mated as prehospital CPAP compared to standard
care, was £9712 per QALY. Given the typical NICE
threshold of £20,000 per QALY, in this analysis it
would be concluded that prehospital CPAP is cost-
effective because it gains QALYs with an acceptable
ICER compared to standard care. Table 2 summarises
mean expected costs and QALYS, ICERs and NMB
for this scenario analysis.
Scatterplot of the incremental expected costs and
QALYs from the PSA are shown in Fig. 4, which indi-
cates much less uncertainty than the base case, with in-
cremental expected costs and effects clustering in the
North East quadrant of the cost-effectiveness plane. The
base case cost-effectiveness acceptability curve (CEAC)
is shown in Fig. 5. The percentage of model runs in
which prehospital CPAP was the most cost-effective
strategy did not exceed 50% at thresholds less than £10,
000/QALY, however, at the £20,000 per QALY prehospi-
tal CPAP was highly likely to be the most cost-effective
strategy (94%).
Value of information analyses demonstrated there was
considerable uncertainty about whether to adopt prehos-
pital CPAP (see Additional file 2 for more details). In
the base case analysis, the population EVPI indicated it
would be worth spending up to £16.5 million on re-
search investigating the effectiveness of prehospital
CPAP in ARF. This is higher in comparison to a popula-
tion EVPI of £3.72 million in the updated meta-analysis
scenario analysis. EVPPI analyses indicated effectiveness
of prehospital CPAP on mortality was the only import-
ant variable for future research, with population of
EVPPI of £16.5 million and £3.72 million respectively in




The base case analysis, using CPAP effectiveness esti-
mates from the ACUTE pilot trial, indicated that stand-
ard oxygen therapy strategy was more effective (mean
incremental QALYs of 0.062), but also more expensive
(mean incremental costs of £351), than prehospital
CPAP with a mean ICER, estimated as standard care
compared to CPAP, of £5685 per QALY. A scenario
analysis, using effectiveness estimates from an updated
meta-analysis, suggested that prehospital CPAP was
more effective (mean incremental QALYs of 0.157), but
also more expensive (mean incremental costs of £1522),
than standard care with a mean ICER, estimated as pre-
hospital CPAP compared to standard care, of £9712 per
QALY.
Interpretation
The decision analytic model showed that the key de-
terminant of cost-effectiveness is whether prehospital
CPAP is effective or not in reducing mortality. This
contrasts to the preceding economic model which
suggested that the incidence of ARF was very import-
ant, secondary to its influence on prehospital CPAP
costs. The O-Two CPAP device used in the ACUTE
model is much cheaper and requires less training
Table 2 Mean expected costs and QALYS, ICERs and NMB for base case and scenario analyses




Base case: ACUTE pilot trial effectiveness data
Standard Care £15,201 1.190 £5685a £8598 £883a 0.67
Prehospital CPAP £14,850 1.128 – £7715 – 0.33
Scenario analysis: Updated network meta-analysis effectiveness estimates
Standard Care £15,201 1.19 – £8598 – 0.06
Prehospital CPAP £16,722 1.35 £9712b £10,209 £1612b 0.94
aMean ICER/incremental NMB estimated as standard care compared to CPAP. *Assuming a threshold value of £20,000 per QALY. b Mean ICER/incremental NMB
estimated as CPAP compared to standard care
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than the system previously examined [13], meaning
that the costs of providing prehospital CPAP and thus
the incidence of ARF is no longer critical in deter-
mining cost-effectiveness.
There is significant uncertainty around what is the
most valid and applicable effectiveness estimate for
prehospital CPAP. The base case analysis, using
ACUTE pilot trial effectiveness data, suggested that
prehospital CPAP was cheaper than standard care.
This arises from increased short term mortality with
fewer patients incurring critical care or lifetime health
costs. However, this also results in fewer lifetime
QALYs, and at the conventional £20,000 threshold
there is a 67% probability that standard care is the
most cost-effective option. The ACUTE pilot trial
should be more representative of NHS ambulance ser-
vices, but the low sample size gives very imprecise ef-
fectiveness estimates and leaves considerable
uncertainty around cost-effectiveness, reflected in the
large population EVPPI for the mortality effectiveness
parameter. Whilst the scenario analysis using updated
meta-analysis effectiveness data gives the opposite
conclusion to the base case and suggests that CPAP
is highly likely to be cost-effective at a threshold of
Fig. 2 Cost-effectiveness plane showing incremental costs and QALYs for standard care compared to prehospital CPAP for base case analysis
using ACUTE effectiveness data
Fig. 3 Cost-effectiveness acceptability curve for the base case analysis using ACUTE effectiveness data. *MAICER: maximum acceptable incremental
cost-effectiveness ratio
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£20,000 per QALY, the population EVPI and EVPPI
for CPAP effectiveness still remains high suggesting
that uncertainty in the effectiveness parameter.
Overall, the economic evaluation indicates that cost-
effectiveness is principally dependent on the clinical
effectiveness of CPAP and it is worthwhile for future
research to reducing the uncertainty in this param-
eter, as suggested by the value of information ana-
lyses. In both the scenarios, the population EVPI and
EVPPI for CPAP effectiveness remained high,
supporting the commissioning of a large pragmatic ef-
fectiveness trial, providing feasibility and plausibility
conditions are met.
Generalisability of findings
The economic model follows recommendations from
NICE and should have good external validity to UK set-
tings. However, it may not be possible to generalise
these results to other populations and jurisdictions with
different health systems due to the potential differences
in the effectiveness, costs, type of patients and service
pathways. The ACUTE trial enrolled patients with non-
differentiated ARF and used a specific disposable CPAP
unit. Base case cost-effectiveness estimates could there-
fore differ if CPAP is used more selectively, or if alterna-
tive CPAP systems are used. Furthermore, the analyses
were from a health care perspective using cost per
Fig. 4 Cost-effectiveness plane showing incremental costs and QALYs for prehospital CPAP compared to standard care in the updated network
meta-analysis scenario analysis
Fig. 5 Cost-effectiveness acceptability curve for the updated meta-analysis scenario analysis. *MAICER: maximum acceptable incremental cost-effectiveness ratio
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QALY approach so these results may not be generalis-
able to settings using other perspectives (e.g. societal
perspective) or other economic evaluation methods (e.g.
cost-benefit analysis or cost-consequence analysis).
Comparison to literature
Only one other economic evaluation of prehospital NIV
for patients with ARF is available [21]. However mean-
ingful comparison with the current study is difficult. In-
hospital effectiveness data were used rather than prehos-
pital data; outcomes were valued as lives saved rather
than QALYs; the model only used a 1-year time horizon;
and probabilistic sensitivity analysis was not performed.
Limitations
This economic evaluation updated a previously pub-
lished decision analytic model [2] and followed NICE
base case recommendations, taking the perspective of
the NHS in England and Wales, valued outcomes as
QALYs, used a lifetime horizon, and included probabilis-
tic sensitivity analysis [9, 17, 18]. The strengths included
detailed costing at the level of the ambulance service;
and use of relevant existing data sources to estimate key
population, cost and outcome parameters. Decision un-
certainty was explored in scenario analyses using differ-
ent effectiveness estimates. Using ACUTE data, directly
relevant to the study setting, for key ARF and effective-
ness parameters in the base case, helped overcome the
main limitations of the preceding economic analysis [2],
which was reliant on potentially estimates from less
pragmatic trials that used physicians and paramedics
with online support to deliver the intervention. However,
the low sample size in the ACUTE pilot trial resulted in
very imprecise effectiveness estimates and leaves consid-
erable uncertainty around cost-effectiveness. In order to
address this uncertainty, scenario analysis was performed
using the updated meta-analysis effectiveness data. In
both analyses, there was large population EVPPI for the
mortality effectiveness parameter suggesting substantial
uncertainty in the effectiveness.
There are limitations in the model design and param-
eterisation which could challenge the internal validity of
results. Within the modelled population there will be a
considerable diversity of patients with differing charac-
teristics, underlying diagnoses, and prognoses. Applying
a cohort methodology, with consequent use of mean
values, impeded an examination of uncertainty due to
heterogeneity. However, competing management strat-
egies are service level interventions, and hence would be
applied to the entire population presenting with ARF
and ostensibly eligible for CPAP. Exploration of hetero-
geneity, for example the cost-effectiveness in different
underlying diseases, is therefore less relevant. The model
assumed that the proportion of patients that would
receive NIV in hospital was similar in both arms, irre-
spective of whether patient received prehospital CPAP.
This appears plausible based from the limited ACUTE
pilot trial data, but it is conceivable that there could be
an association between the effectiveness of treatment
during the EMS interval and ED management.
It was also assumed that the lifetime QALYs were
same for all survivors, irrespective of whether they were
in the standard care or prehospital CPAP arm. There
was a limited evidence base available to parameterise
lifetime QALYs and costs of care, with data provided by
the 3CPO trial [12]. This study enrolled patients with
pulmonary oedema receiving emergency department
NIV, rather than the undifferentiated EMS ARF cases
relevant for prehospital CPAP. However, baseline char-
acteristics of participants in 3CPO appear similar to
those included in ACUTE. Although unproven, this ap-
pears to be reasonable, as CPAP would only be expected
to help with acute presentations and short term out-
comes, rather than modify underlying chronic diseases.
Conclusions
The cost-effectiveness of prehospital CPAP depends
upon the estimate of effectiveness. When based on a
small pragmatic feasibility trial, standard oxygen therapy
is cost-effective. When based on meta-analysis of hetero-
geneous trials, CPAP is cost-effective. Value of informa-
tion analyses support the commissioning of a large
pragmatic effectiveness trial, providing feasibility and
plausibility conditions are met.
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